TrialPituitary2016

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.

Maria Fleseriu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.